AbbVie Drops 3.1% as New Skyrizi Phase 3 Data Hits the Wire

AbbVie slid steadily through the session, ending near $273.85 as fresh Phase 3 AFFIRM trial data for subcutaneous Skyrizi in Crohn's disease crossed the wire. The timing of the decline and the data release were essentially simultaneous, making the market's reaction to that readout the central story of the session.

Skyrizi is the company's designated growth engine for the post-Humira era, the asset management has pointed to as the clearest answer to the revenue gap left by Humira's biosimilar competition. A market that reads new clinical data and immediately sends the stock down 3.1% is signaling real doubt about what those AFFIRM results actually show.

Selling was persistent rather than a single sharp capitulation, a pattern that tends to reflect investors repositioning rather than a knee-jerk reaction to a headline they plan to walk back.

For investors now, the question is how analysts and the company itself characterize the AFFIRM data in the hours and days that follow. If Skyrizi's Crohn's profile is genuinely strong, the selloff creates an entry point. If the data raised questions about efficacy or safety that the market has correctly priced in, the pressure on the stock is unlikely to lift quickly.